The DOI matches its Crossref record; 61 of the 61 references it cites were found in a registry or an index.
Parkinson's disease: Autoimmunity and neuroinflammation
Open accessAbstract
Parkinson's disease is a neurodegenerative disease that causes the death of dopaminergic neurons in the substantia nigra. The resulting dopamine deficiency in the basal ganglia leads to a movement disorder that is characterized by classical parkinsonian motor symptoms. Parkinson's disease is recognized as the most common neurodegenerative disorder after Alzheimer's disease. PD ethiopathogenesis remains to be elucidated and has been connected to genetic, environmental and immunologic conditions. The past decade has provided evidence for a significant role of the immune system in PD pathogenesis, either through inflammation or an autoimmune response. Several autoantibodies directed at antigens associated with PD pathogenesis have been identified in PD patients. This immune activation may be the cause of, rather than a response to, the observed neuronal loss. Parkinsonian motor symptoms include bradykinesia, muscular rigidity and resting tremor. The non-motor features include olfactory dysfunction, cognitive impairment, psychiatric symptoms and autonomic dysfunction. Microscopically, the specific degeneration of dopaminergic neurons in the substantia nigra and the presence of Lewy bodies, which are brain deposits containing a substantial amount of α-synuclein, have been recognized. The progression of Parkinson's disease is characterized by a worsening of motor features; however, as the disease progresses, there is an emergence of complications related to long-term symptomatic treatment. The available therapies for Parkinson's disease only treat the symptoms of the disease. A major goal of Parkinson's disease research is the development of disease-modifying drugs that slow or stop the neurodegenerative process. Drugs that enhance the intracerebral dopamine concentrations or stimulate dopamine receptors remain the mainstay treatment for motor symptoms. Immunomodulatory therapeutic strategies aiming to attenuate PD neurodegeneration have become an attractive option and warrant further investigation.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Epidemiology of Parkinson's disease
de Lau, L. M., & Breteler, M. M. (2006) · The Lancet Neurology · doi:10.1016/s1474-4422(06)70471-9 · Cited by 4,110
Lagouge, M., Argmann, C., Gerhart-Hines, Z., Meziane, H., Lerin, C., Daussin, F., Messadeq, N., Milne, J., Lambert, P., Elliott, P., et al. (2006) · Cell · doi:10.1016/j.cell.2006.11.013 · Cited by 4,057 · cited 1×
“These activators include fibrates and rosiglitazone (PPAR) [62,63], metformin [64], pyrroloquinoline quinone [65], 5-aminoimidazole-4-carboxamide ribonucleotide (AICAR) (AMPK) [66] and resveratrol (Sirt1) [67].”
BackgroundThe relevance of the Lewy body to the pathogenesis of idiopathic Parkinson's disease.
Gibb, W. R., & Lees, A. J. (1988) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp.51.6.745 · Cited by 3,481
Projected number of people with Parkinson disease in the most populous nations, 2005 through 2030
Dorsey, E. R., Constantinescu, R., Thompson, J. P., Biglan, K. M., Holloway, R. G., Kieburtz, K., Marshall, F. J., Ravina, B. M., Schifitto, G., Siderowf, A., et al. (2007) · Neurology · doi:10.1212/01.wnl.0000247740.47667.03 · Cited by 2,472
The Sydney multicenter study of Parkinson's disease: The inevitability of dementia at 20 years
Hely, M. A., Reid, W. G. J., Adena, M. A., Halliday, G. M., & Morris, J. G. L. (2008) · Movement Disorders · doi:10.1002/mds.21956 · Cited by 2,246
The prevalence of Parkinson's disease: a systematic review and meta-analysis
Pringsheim, T., Jette, N., Frolkis, A., & Steeves, T. D. L. (2014) · Movement Disorders · doi:10.1002/mds.25945 · Cited by 2,188
Incidence of Parkinson's Disease: Variation by Age, Gender, and Race/Ethnicity
Van Den Eeden, S. K. (2003) · American Journal of Epidemiology · doi:10.1093/aje/kwg068 · Cited by 1,747
Pharmacological Treatment of Parkinson Disease: A Review
Connolly, B. S., & Lang, A. E. (2014) · JAMA · doi:10.1001/jama.2014.3654 · Cited by 1,498
Goedert, M., Spillantini, M. G., Del Tredici, K., & Braak, H. (2013) · Nature Reviews Neurology · doi:10.1038/nrneurol.2012.242 · Cited by 1,190
Seppi, K., Weintraub, D., Coelho, M., Perez‐Lloret, S., Fox, S. H., Katzenschlager, R., Hametner, E., Poewe, W., Rascol, O., Goetz, C. G., et al. (2011) · Movement Disorders · doi:10.1002/mds.23884 · Cited by 1,141
Sydney multicenter study of Parkinson's disease: Non‐L‐dopa–responsive problems dominate at 15 years
Hely, M. A., Morris, J. G. L., Reid, W. G. J., & Trafficante, R. (2005) · Movement Disorders · doi:10.1002/mds.20324 · Cited by 1,050
2014 Alzheimer's disease facts and figures
Alzheimer's Association (2014) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2014.02.001 · Cited by 1,020
Parkinson's disease: from monogenic forms to genetic susceptibility factors
Lesage, S., & Brice, A. (2009) · Human Molecular Genetics · doi:10.1093/hmg/ddp012 · Cited by 945
Meta‐analysis of early nonmotor features and risk factors for Parkinson disease
Noyce, A. J., Bestwick, J. P., Silveira‐Moriyama, L., Hawkes, C. H., Giovannoni, G., Lees, A. J., & Schrag, A. (2012) · Annals of Neurology · doi:10.1002/ana.23687 · Cited by 778
Nonsteroidal Anti-inflammatory Drugs and the Risk of Parkinson Disease
Chen, H., Zhang, S. M., Hernán, M. A., Schwarzschild, M. A., Willett, W. C., Colditz, G. A., Speizer, F. E., & Ascherio, A. (2003) · Archives of Neurology · doi:10.1001/archneur.60.8.1059 · Cited by 634
DJ-1 and α-synuclein in human cerebrospinal fluid as biomarkers of Parkinson’s disease
Hong, Z., Shi, M., Chung, K. A., Quinn, J. F., Peskind, E. R., Galasko, D., Jankovic, J., Zabetian, C. P., Leverenz, J. B., Baird, G., et al. (2010) · Brain · doi:10.1093/brain/awq008 · Cited by 615
Identifying prodromal Parkinson's disease: Pre‐Motor disorders in Parkinson's disease
Postuma, R. B., Aarsland, D., Barone, P., Burn, D. J., Hawkes, C. H., Oertel, W., & Ziemssen, T. (2012) · Movement Disorders · doi:10.1002/mds.24996 · Cited by 612
Fox, S. H., Katzenschlager, R., Lim, S., Ravina, B., Seppi, K., Coelho, M., Poewe, W., Rascol, O., Goetz, C. G., & Sampaio, C. (2011) · Movement Disorders · doi:10.1002/mds.23829 · Cited by 523
The History of Parkinson's Disease: Early Clinical Descriptions and Neurological Therapies
Goetz, C. G. (2011) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a008862 · Cited by 470
LRRK2 Inhibition Attenuates Microglial Inflammatory Responses
Moehle, M. S., Webber, P. J., Tse, T., Sukar, N., Standaert, D. G., DeSilva, T. M., Cowell, R. M., & West, A. B. (2012) · The Journal of Neuroscience · doi:10.1523/jneurosci.5601-11.2012 · Cited by 463
The NINDS NET-PD Investigators (2006) · Neurology · doi:10.1212/01.wnl.0000201252.57661.e1 · Cited by 453
A possible role for humoral immunity in the pathogenesis of Parkinson's disease
Orr, C. F., Rowe, D. B., Mizuno, Y., Mori, H., & Halliday, G. M. (2005) · Brain · doi:10.1093/brain/awh625 · Cited by 350
Wilms, H., Rosenstiel, P., Sievers, J., Deuschl, G., Zecca, L., & Lucius, R. (2003) · The FASEB Journal · doi:10.1096/fj.02-0314fje · Cited by 337
Incidence and remaining lifetime risk of Parkinson disease in advanced age
Driver, J. A., Logroscino, G., Gaziano, J. M., & Kurth, T. (2009) · Neurology · doi:10.1212/01.wnl.0000341769.50075.bb · Cited by 298
Liu, B., Gao, H.-M., & Hong, J.-S. (2003) · Environmental Health Perspectives · doi:10.1289/ehp.6361 · Cited by 285
Prospects for Minocycline Neuroprotection
Plane, J. M., Shen, Y., Pleasure, D. E., & Deng, W. (2010) · Archives of Neurology · doi:10.1001/archneurol.2010.191 · Cited by 276
Lewy body–type degeneration in cardiac plexus in Parkinson’s and incidental Lewy body diseases
Iwanaga, K., Wakabayashi, K., Yoshimoto, M., Tomita, I., Satoh, H., Takashima, H., Satoh, A., Seto, M., Tsujihata, M., & Takahashi, H. (1999) · Neurology · doi:10.1212/wnl.52.6.1269 · Cited by 274
Chowanadisai, W., Bauerly, K. A., Tchaparian, E., Wong, A., Cortopassi, G. A., & Rucker, R. B. (2010) · Journal of Biological Chemistry · doi:10.1074/jbc.m109.030130 · Cited by 259
Zhang, W., Phillips, K., Wielgus, A. R., Liu, J., Albertini, A., Zucca, F. A., Faust, R., Qian, S. Y., Miller, D. S., Chignell, C. F., et al. (2011) · Neurotoxicity Research · doi:10.1007/s12640-009-9140-z · Cited by 257
Coelho, M., & Ferreira, J. J. (2012) · Nature Reviews Neurology · doi:10.1038/nrneurol.2012.126 · Cited by 250
On the origin and significance of neuromelanin.
Dg, G. (1979) · PubMed · Cited by 223
Suwa, M., Egashira, T., Nakano, H., Sasaki, H., & Kumagai, S. (2006) · Journal of Applied Physiology · doi:10.1152/japplphysiol.00255.2006 · Cited by 210
Cerebrospinal fluid biomarkers in Parkinson disease
Parnetti, L., Castrioto, A., Chiasserini, D., Persichetti, E., Tambasco, N., El-Agnaf, O., & Calabresi, P. (2013) · Nature Reviews Neurology · doi:10.1038/nrneurol.2013.10 · Cited by 209
AMP-Activated Protein Kinase-Regulated Activation of the PGC-1α Promoter in Skeletal Muscle Cells
Irrcher, I., Ljubicic, V., Kirwan, A. F., & Hood, D. A. (2008) · PLoS ONE · doi:10.1371/journal.pone.0003614 · Cited by 208
Regulation of LRRK2 Expression Points to a Functional Role in Human Monocyte Maturation
Thévenet, J., Pescini Gobert, R., Hooft van Huijsduijnen, R., Wiessner, C., & Sagot, Y. J. (2011) · PLoS ONE · doi:10.1371/journal.pone.0021519 · Cited by 189
Autoantibodies to alpha‐synuclein in inherited Parkinson’s disease
Papachroni, K. K., Ninkina, N., Papapanagiotou, A., Hadjigeorgiou, G. M., Xiromerisiou, G., Papadimitriou, A., Kalofoutis, A., & Buchman, V. L. (2007) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2006.04365.x · Cited by 185
Yanamandra, K., Gruden, M. A., Casaite, V., Meskys, R., Forsgren, L., & Morozova-Roche, L. A. (2011) · PLoS ONE · doi:10.1371/journal.pone.0018513 · Cited by 171
Imaging biomarkers in Parkinson's disease
Brooks, D. J., & Pavese, N. (2011) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2011.08.009 · Cited by 170
7 tesla magnetic resonance imaging: A closer look at substantia nigra anatomy in Parkinson's disease
Lehéricy, S., Bardinet, É., Poupon, C., Vidailhet, M., & François, C. (2014) · Movement Disorders · doi:10.1002/mds.26043 · Cited by 158
The mosaic of autoimmunity: prediction, autoantibodies, and therapy in autoimmune diseases--2008.
Shoenfeld, Y., Blank, M., Abu‐Shakra, M., Amital, H., Barzilai, O., Berkun, Y., Bizzaro, N., Gilburd, B., Zandman‐Goddard, G., Katz, U., et al. (2008) · PubMed · Cited by 154
Nonsteroidal anti‐inflammatory drugs and risk of Parkinson's disease
Ton, T. G. N., Heckbert, S. R., Longstreth, W. T., Jr., Rossing, M. A., Kukull, W. A., Franklin, G. M., Swanson, P. D., Smith‐Weller, T., & Checkoway, H. (2006) · Movement Disorders · doi:10.1002/mds.20856 · Cited by 141
Experimental Destruction of Substantia Nigra Initiated by Parkinson Disease Immunoglobulins
Chen, S., Le, W.-D., Xie, W., Alexianu, M. E., Engelhardt, J. I., Siklós, L., & Appel, S. H. (1998) · Archives of Neurology · doi:10.1001/archneur.55.8.1075 · Cited by 130
PPARδ, but not PPARα, activates PGC-1α gene transcription in muscle
Hondares, E., Pineda-Torra, I., Iglesias, R., Staels, B., Villarroya, F., & Giralt, M. (2007) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2007.01.092 · Cited by 120
Coffee, ADORA2A, and CYP1A2: the caffeine connection in Parkinson’s disease
Popat, R. A., Eeden, S. K. V. D., Tanner, C. M., Kamel, F., Umbach, D. M., Marder, K. S., Mayeux, R. P., Ritz, B. R., Ross, G. W., Petrovitch, H., et al. (2011) · European Journal of Neurology · doi:10.1111/j.1468-1331.2011.03353.x · Cited by 119
Magnetic resonance imaging of the substantia nigra in Parkinson's disease
Lehéricy, S., Sharman, M. A., dos Santos, C. L., Paquin, R., & Galléa, C. (2012) · Movement Disorders · doi:10.1002/mds.25015 · Cited by 112
γδ+ T cells are increased in patients with Parkinson's disease
Fiszer, U., Mix, E., Fredrikson, S., Kostulas, V., Olsson, T. P., & Link, H. (1994) · Journal of the Neurological Sciences · doi:10.1016/0022-510x(94)90154-6 · Cited by 108
Pardo, R., Enguix, N., Lasheras, J., Felíu, J. E., Kralli, A., & Villena, J. A. (2011) · PLoS ONE · doi:10.1371/journal.pone.0026989 · Cited by 101
PGC‐1α activation as a therapeutic approach in mitochondrial disease
Wenz, T. (2009) · IUBMB Life · doi:10.1002/iub.261 · Cited by 100
He, Y., Le, W., & Appel, S. H. (2002) · Experimental Neurology · doi:10.1006/exnr.2002.7946 · Cited by 97
Anti-melanin antibodies are increased in sera in Parkinson's disease
Double, K. L., Rowe, D. B., Carew‐Jones, F., Hayes, M., Chan, D. K. Y., Blackie, J., Corbett, A. J., Joffe, R., Fung, V. S. C., Morris, J. G., et al. (2009) · Experimental Neurology · doi:10.1016/j.expneurol.2009.03.002 · Cited by 85
Abramsky, O., & LITVIN, Y. (1978) · PubMed · Cited by 84
Olfactory pathogenesis of idiopathic Parkinson disease revisited
Lerner, A., & Bagic, A. I. (2008) · Movement Disorders · doi:10.1002/mds.22066 · Cited by 80
Anti-GM1 ganglioside antibodies in Parkinson's disease
Zappia, M., Crescibene, L., Bosco, D., et al. (2002) · Acta Neurologica Scandinavica · doi:10.1034/j.1600-0404.2002.01240.x · Cited by 65
Luedtke, R. R., Griffin, S. A., Conroy, S. S., Jin, X., Pinto, A., & Sesack, S. R. (1999) · Journal of Neuroimmunology · doi:10.1016/s0165-5728(99)00142-3 · Cited by 59
Effects of Cerebrospinal Fluid From Patients With Parkinson Disease on Dopaminergic Cells
Le, W., Rowe, D. B., Jankovic, J. J., Xie, W., & Appel, S. H. (1999) · Archives of Neurology · doi:10.1001/archneur.56.2.194 · Cited by 56
Immunology, Autoimmunity, and Autoantibodies in Parkinson’s Disease
Benkler, M., Agmon‐Levin, N., Hassin‐Baer, S., Cohen, O. S., Ortega‐Hernandez, O., Levy, A., Moscavitch, S.-D., Szyper‐Kravitz, M., Damianovich, M., Blank, M., et al. (2011) · Clinical Reviews in Allergy & Immunology · doi:10.1007/s12016-010-8242-y · Cited by 50
Autoimmunity, dendritic cells and relevance for Parkinson’s disease
Koutsilieri, E., Lutz, M. B., & Scheller, C. (2012) · Journal of Neural Transmission · doi:10.1007/s00702-012-0842-7 · Cited by 50
Neuromelanin is an immune stimulator for dendritic cells in vitro
Oberländer, U., Pletinckx, K., Döhler, A., Müller, N., Lutz, M. B., Arzberger, T., Riederer, P. F., Gerlach, M., Koutsilieri, E., & Scheller, C. (2011) · BMC Neuroscience · doi:10.1186/1471-2202-12-116 · Cited by 48
Carvey, P. M., McRae‐Degueurce, A., Lint, T. F., Ptak, L. R., Lo, E. S., Goetz, C., & Klawans, H. L. (1991) · Neurology · doi:10.1212/wnl.41.5_suppl_2.53 · Cited by 47
Advances in the genetics of Parkinson's disease
Rosner, S., Giladi, N., & Orr‐Urtreger, A. (2008) · Acta Pharmacologica Sinica · doi:10.1111/j.1745-7254.2008.00731.x · Cited by 40
PARKINSON’S DISEASE, AUTOIMMUNITY, AND OLFACTION
Benkler, M., Agmon‐Levin, N., & Shoenfeld, Y. (2009) · International Journal of Neuroscience · doi:10.3109/00207450903178786 · Cited by 30
Research works printed but not linked: 5
- Manyam, 1999, Traditional and complementary therapies in Parkinson's disease, Adv Neurol, 80, 565
- Zhang, 2006, Early descriptions of Parkinson's disease in ancient China, Arch Neurol, 63, 782, 10.1001/archneur.63.5.782 · doi:10.1001/archneur.63.5.782
- Møller, 1989, Parkinson's disease and autoimmunity, Acta Neurol Scand, 79, 173, 10.1111/j.1600-0404.1989.tb03733.x · doi:10.1111/j.1600-0404.1989.tb03733.x
- Myers, 1976, Evidence for a dopamine receptor antibody, Biochem Biophys Res Commun, 72, 1311, 10.1016/S0006-291X(76)80158-1 · doi:10.1016/s0006-291x(76)80158-1
- Farooqui, 1991, Antibodies against synthetic peptides predicted from the nucleotide sequence of D2 receptor recognize native dopamine receptor protein in rat striatum, J Neurochem, 57, 1363, 10.1111/j.1471-4159.1991.tb08302.x · doi:10.1111/j.1471-4159.1991.tb08302.x
Cited by
The genetics of Parkinson disease
Deng, H., Wang, P., & Jankovic, J. (2018) · Ageing Research Reviews · doi:10.1016/j.arr.2017.12.007 · Cited by 530
Pyroptosis in health and disease: mechanisms, regulation and clinical perspective
Liu, Y., Pan, R., Ouyang, Y., Gu, W., Xiao, T., Yang, H., Tang, L., Wang, H., Xiang, B., & Chen, P. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01958-2 · Cited by 337
Regulation of Ketone Body Metabolism and the Role of PPARα
Grabacka, M., Pierzchalska, M., Dean, M., & Reiss, K. (2016) · International Journal of Molecular Sciences · doi:10.3390/ijms17122093 · Cited by 305
Biomarker of Neuroinflammation in Parkinson’s Disease
Liu, T.-W., Chen, C.-M., & Chang, K.-H. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23084148 · Cited by 259
Cheng, J., Liao, Y., Dong, Y., Hu, H., Yang, N., Kong, X., Li, S., Li, X., Guo, J., Qin, L., et al. (2020) · Autophagy · doi:10.1080/15548627.2020.1719723 · Cited by 233
Metadata
- Authors
- De Virgilio, A., Greco, A., Fabbrini, G., Inghilleri, M., Rizzo, M. I., Gallo, A., Conte, M., Rosato, C., Ciniglio Appiani, M., & de Vincentiis, M.
- Venue
- Autoimmunity Reviews
- Publisher
- Elsevier BV
- Published
- 2016-10
- Volume
- 15
- Issue
- 10
- Pages
- 1005-1011
- ISSN
- 1568-9972 (ISSN-L)
- OpenAlex
- W2494229447
- Cited by
- 389
- References
- 61
- FWCI
- 20.17
- Type
- journal article
- Language
- en
- Update notices
- erratum (2016-12-01)
- Open access
- green
- Licence
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- www.elsevier.com/legal/tdmrep-license (tdm)
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.